Analyst: New UK monkeypox strategy might boost Bavarian Nordic orders
The UK plans to offer Bavarian Nordic’s vaccine, Imvanex, to a broader segment of people at risk of exposure. Wider use could lead to more orders from governments, assesses one analyst.
.jpg)
by marketwire, translated by daniel pedersen
On Tuesday, the UK announced plans to provide Bavarian Nordic’s vaccine, Imvanex, to a wider segment of people at-risk of exposure, including gay and bisexual men. Previously, vaccination was only recommended for those who had been in close contact with someone carrying the infection.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
UK to widen vaccine offer to help control monkeypox spread
For subscribers
Bavarian Nordic CFO: More monkeypox orders may follow
For subscribers
.jpg)
.jpg&w=384&q=75)
